F
$ Value
$1.7M
Shares
11,002
Price
$156
Filed
May 5
Insider
Name
REED JOHN C
Title
EVP, Innovative Medicine, R&D
CIK
0001181561
Roles
Officer
Transaction Details
Transaction Date
2025-05-01
Code
F
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
29,795
Footnotes
Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. | Shares withheld for payment of taxes upon vesting of RSUs.
Filing Info
REED JOHN C's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-17 | JNJ | M | $3.4M |
| 2026-02-17 | JNJ | ▼ | $5.3M |
| 2026-02-17 | JNJ | M | $4.7M |
| 2026-02-17 | JNJ | ▼ | $7.3M |
| 2026-02-17 | JNJ | ▼ | $555K |
| 2026-02-17 | JNJ | M | $0 |
| 2026-02-17 | JNJ | M | $0 |
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | F | $94K |
| 2026-02-15 | JNJ | M | $0 |
Other Insiders at JNJ (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
REED JOHN C
EVP, Innovative Medicine, R&D
|
— | $13.1M | 2026-02-17 |
|
Duato Joaquin
CEO and Chairman of the Board
|
— | $22.1M | 2026-02-15 |
|
Wolk Joseph J
Exec VP, CFO
|
— | $21.8M | 2026-02-17 |
|
Taubert Jennifer L
EVP, WWC. Innovative Medicine
|
— | — | 2026-02-15 |
|
Wengel Kathryn E
EVP, Chief TO and Risk Officer
|
— | — | 2026-02-15 |
|
Decker Robert J
VP Corporate Controller
|
— | — | 2026-02-15 |
|
Swanson James D.
EVP, CIO
|
— | $15.1M | 2026-02-17 |
|
Broadhurst Vanessa
EVP, Global Corp Affairs
|
— | $1.5M | 2026-02-17 |
|
Forminard Elizabeth
EVP, Chief Legal Officer
|
— | — | 2026-02-15 |
|
Schmid Timothy
EVP, WW Chair, MedTech
|
— | $5.5M | 2026-02-18 |
|
Mulholland Kristen
EVP, Chief HR Officer
|
— | — | 2026-02-15 |